Diabetes Products Should Be Exempt From Competitive Bidding – Panel
This article was originally published in The Gray Sheet
Executive Summary
Supplier and manufacturer stakeholders are urging CMS to exclude blood glucose testing products from the impending DMEPOS competitive bidding program